Trop­i­cal dis­ease PRV fix didn’t stop No­var­tis from win­ning an­oth­er

Back in 2017, a new law was en­act­ed, known as the FDA Reau­tho­riza­tion Act (FDARA), which con­tained not on­ly the new user fee pro­grams for phar­ma­ceu­ti­cals, med­ical de­vices, gener­ics and biosim­i­lars, but al­so a slight tweak to the trop­i­cal dis­ease pri­or­i­ty re­view vouch­er (PRV) pro­gram.

The change was meant to en­sure that com­pa­nies win­ning PRVs ac­tu­al­ly per­formed some of the clin­i­cal work to bring the trop­i­cal dis­ease drug to mar­ket in the US, and that the drugs “were not sub­mit­ted as part of an ap­pli­ca­tion for mar­ket­ing ap­proval or li­cen­sure by a reg­u­la­to­ry au­thor­i­ty in In­dia, Brazil, Thai­land, or any coun­try that is a mem­ber of the Phar­ma­ceu­ti­cal In­spec­tion Con­ven­tion or the Phar­ma­ceu­ti­cal In­spec­tion Co­op­er­a­tion Scheme.”

Part of the rea­son these changes were made is that com­pa­nies had abused the pre­vi­ous sys­tem. For ex­am­ple, No­var­tis won the first-award­ed PRV for an an­ti­malar­i­al drug that crit­ics con­tend had been avail­able in de­vel­op­ing coun­tries for years and was first reg­is­tered in 1999.

Sim­i­lar­ly, this week, No­var­tis was re­ward­ed with an­oth­er PRV for win­ing FDA ap­proval for Egat­en (tri­claben­da­zole), which is used to treat peo­ple with fas­ci­o­lia­sis.

Doc­tors With­out Bor­ders (MSF), while crit­i­ciz­ing the PRV pro­gram in gen­er­al for not work­ing “as it was de­signed for peo­ple des­per­ate­ly in need of new and af­ford­able med­i­cines for ne­glect­ed dis­eases,” al­so notes that tri­claben­da­zole was reg­is­tered in Egypt in 1998 and lat­er in France by 2002. Ad­di­tion­al­ly, the drug was placed on the WHO Es­sen­tial Med­i­cines List since at least 2002, MSF said.

So why didn’t the changes made in FDARA stop No­var­tis from win­ning a PRV?

The FDA ex­plained to Fo­cus: “These new el­i­gi­b­li­ty re­quire­ments ap­ply to ap­pli­ca­tions sub­mit­ted af­ter Sep­tem­ber 30, 2017, but did not ap­ply to No­var­tis’s ap­pli­ca­tion.” And No­var­tis con­firmed to Fo­cus that the ap­pli­ca­tion was sub­mit­ted be­fore that date. “The changes made to the trop­i­cal dis­ease PRV pro­gram in FDARA (Sec. 611) do not ap­ply to our ap­pli­ca­tion.”

The com­pa­ny al­so said that it ran mul­ti­ple clin­i­cal in­ves­ti­ga­tions of tri­claben­da­zole and sub­mit­ted da­ta from a col­lec­tion of more than 20 clin­i­cal stud­ies, sup­port­ing the ef­fi­ca­cy and safe­ty pro­file.

And un­like the rare dis­ease drug Fir­dapse (am­i­fam­pri­dine), a pre­vi­ous­ly un­ap­proved drug that was pro­vid­ed free of charge and now will cost $375,000 af­ter FDA ap­proval, No­var­tis said last year it re­newed an agree­ment with the WHO to ex­tend the drug’s do­na­tion un­til 2022, ex­pect­ing to reach 300,000 pa­tients per year.

Rachel Sachs

Rachel Sachs, as­so­ciate pro­fes­sor of law at Wash­ing­ton Uni­ver­si­ty in St. Louis, told Fo­cus that there’s still a dif­fer­ence in type be­tween the prod­ucts win­ning PRVs for ne­glect­ed trop­i­cal dis­eases and rare pe­di­atric dis­ease treat­ments. The ones for rare pe­di­atric can charge high­er prices, but that’s not the case in trop­i­cal dis­eases.

“It may well be that these [FDARA] re­forms will be ef­fec­tive,” she added.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

Here comes the oral GLP-1 drug for di­a­betes — but No­vo Nordisk is­n't dis­clos­ing Ry­bel­sus price just yet

Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.

Rybelsus will be the first GLP-1 pill to enter the type 2 diabetes market — a compelling offering that analysts have pegged as a blockbuster drug with sales estimates ranging from $2 billion to $5 billion.

Ozempic, the once-weekly injectable formulation of semaglutide, brought in around $552 million (DKK 3.75 billion) in the first half of 2019.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Oxitec biologist releases genetically modified mosquitoes in Piracicaba, Brazil in 2016 [credit: Getty Images]

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.

But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.